Alkem, Zydus Life: Nomura’s top picks to bet on Rs 12,000 crore generic Semaglutide opportunity
- Posted on March 23, 2026
- By Financial Express
- 5 Views
Alkem, Zydus Life: Nomura’s top picks to bet on Rs 12,000 crore generic Semaglutide opportunity
Nomura has a ‘Buy’ rating on Zydus Lifesciences, with the stock at Rs 891 and a target price of Rs 1,140, implying about 28% upside.
